COLLEGIUM PHARMACEUTICAL INC
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | |
|---|---|
| | COLLEGIUM PHARMACEUTICAL, INC. |
| | |
| | By: /s/ Joseph Ciaffoni |
| | Joseph Ciaffoni |
| | Chief Executive Officer |
| | | | | |
|---|---|---|---|---|
| Signature | | Title | | Date |
| | | | | |
| /s/ Joseph Ciaffoni | | President and Chief Executive Officer (Principal Executive Officer) and Director | | February 22, 2024 |
| Joseph Ciaffoni | | | | |
| | | | | |
| | | | | |
| /s/ Colleen Tupper | | Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | | February 22, 2024 |
| Colleen Tupper | | | | |
| | | | | |
| /s/ Michael T. Heffernan, R.Ph. | | Chairman of the Board | | February 22, 2024 |
| Michael T. Heffernan, R.Ph. | | | | |
| | | | | |
| /s/ Rita Balice-Gordon, Ph.D. | | Director | | February 22, 2024 |
| Rita Balice-Gordon, Ph.D. | | | | |
| | | | | |
| /s/ Garen G. Bohlin | | Director | | February 22, 2024 |
| Garen G. Bohlin | | | | |
| | | | | |
| /s/ John A. Fallon, M.D. | | Director | | February 22, 2024 |
| John A. Fallon, M.D. | | | | |
| | | | | |
| /s/ John G. Freund, M.D. | | Director | | February 22, 2024 |
| John G. Freund, M.D. | | | | |
| | | | | |
| /s/ Gwen Melincoff | | Director | | February 22, 2024 |
| Gwen Melincoff | | | | |
| | | | | |
| /s/ Gino Santini | | Director | | February 22, 2024 |
| Gino Santini | | | | |
| | | | | |
| /s/ Neil McFarlane | | Director | | February 22, 2024 |
| Neil McFarlane | | | | |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated.
Index to Consolidated Financial Statements
| Audited Consolidated Financial Statements | Pages | |
|---|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID 34) | F-2 | |
| | | |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-4 | |
| | | |
| Consolidated Statements of Operations for the Years Ended December 31, 2023, 2022, and 2021 | F-5 | |
| | | |
| Consolidated Statements of Shareholders' Equity for the Years Ended December 31, 2023, 2022, and 2021 | F-7 | |
| | | |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023, 2022, and 2021 | F-8 | |
| | | |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.